» Articles » PMID: 22398093

Low-dose Smoking Resumption in Ex-smokers with Refractory Ulcerative Colitis

Overview
Date 2012 Mar 9
PMID 22398093
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: Ulcerative colitis (UC) is primarily a disease of non-smokers. Ex-smokers may have a more refractory disease course and anecdotal evidence in non-controlled clinical trials have suggested that smoking resumption, or the administration of nicotine, may ameliorate signs and symptoms of UC in ex-smokers. We report outcomes of ex-smokers with refractory UC who resumed low-dose cigarette smoking.

Methods: 17 ex-smokers with refractory UC were identified. Clinical remission was defined as a disease activity index score of 0.

Results: Two out of 17 patients refused the recommendation to resume smoking. Of the 15 patients who resumed smoking, the mean daily number of cigarettes was 8.6. Fourteen out of those 15 patients who resumed smoking were able to maintain prolonged clinical remission off steroids. One out of the 15 patients failed to improve and required oral steroids. Another patient was compelled to quit smoking since he became addicted. His disease flared after maintaining a prolonged remission of 3 years and he eventually underwent surgery. Three out of these 15 patients switched from cigarettes smoking to nicotine compounds and continued to maintain remission.

Conclusion: Resumption of low dose smoking in a selected group of ex-smokers with refractory UC may ameliorate signs and symptoms. Quality of life, medication side effects, and smoking risk factors should all be considered and discussed with patients. Smokers should be meticulously followed for compliance with "low-dose" regimen and all associated smoking risks.

Citing Articles

Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.

Rubin D, Torres J, Regueiro M, Reinisch W, Prideaux L, Kotze P Crohns Colitis 360. 2024; 6(1):otae004.

PMID: 38425446 PMC: 10904100. DOI: 10.1093/crocol/otae004.


Evidence-based pathogenesis and treatment of ulcerative colitis: A causal role for colonic epithelial hydrogen peroxide.

Pravda J World J Gastroenterol. 2022; 28(31):4263-4298.

PMID: 36159014 PMC: 9453768. DOI: 10.3748/wjg.v28.i31.4263.


Pouchitis: insight into the pathogenesis and clinical aspects.

de Negreiros L, Pascoal L, Genaro L, Silva J, Rodrigues B, Camargo M Am J Transl Res. 2022; 14(7):4406-4425.

PMID: 35958439 PMC: 9360866.


Medical treatment of pouchitis: a guide for the clinician.

Rabbenou W, Chang S Therap Adv Gastroenterol. 2021; 14:17562848211023376.

PMID: 34249146 PMC: 8239975. DOI: 10.1177/17562848211023376.


A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis.

Rubin D, Traboulsi C, Rai V Gastroenterol Hepatol (N Y). 2021; 17(2):59-66.

PMID: 34035764 PMC: 8132723.